{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:00:57Z","timestamp":1793678457446,"version":"4.5.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170197"],"award-info":[{"award-number":["82170197"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2022D015"],"award-info":[{"award-number":["2022D015"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2024R1036"],"award-info":[{"award-number":["2024R1036"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010877","name":"Shenzhen Science and Technology Innovation Commission","doi-asserted-by":"publisher","award":["JCYJ20220530143403007"],"award-info":[{"award-number":["JCYJ20220530143403007"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024A1515010076"],"award-info":[{"award-number":["2024A1515010076"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-56506-5","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T02:44:11Z","timestamp":1738291451000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["EZH2 serves as a viable therapeutic target for myeloma-induced osteolytic bone destruction"],"prefix":"10.1038","volume":"16","author":[{"given":"Rui","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0677-8097","authenticated-orcid":false,"given":"Zhiqiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2314-5136","authenticated-orcid":false,"given":"Huan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"key":"56506_CR1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo, A. & Anderson, K. Multiple myeloma. N. Engl. J. Med. 364, 1046\u20131060 (2011).","journal-title":"N. Engl. J. Med."},{"key":"56506_CR2","doi-asserted-by":"publisher","first-page":"353ra113","DOI":"10.1126\/scitranslmed.aad8949","volume":"8","author":"H Liu","year":"2016","unstructured":"Liu, H. et al. Thymidine phosphorylase exerts complex effects on bone resorption and formation in myeloma. Sci. Transl. Med. 8, 353ra113 (2016).","journal-title":"Sci. Transl. Med."},{"key":"56506_CR3","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/s12276-024-01157-7","volume":"56","author":"N Takegahara","year":"2024","unstructured":"Takegahara, N., Kim, H. & Choi, Y. Unraveling the intricacies of osteoclast differentiation and maturation: insight into novel therapeutic strategies for bone-destructive diseases. Exp. Mol. Med. 56, 264\u2013272 (2024).","journal-title":"Exp. Mol. Med."},{"key":"56506_CR4","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1182\/blood-2006-05-026112","volume":"108","author":"N Giuliani","year":"2006","unstructured":"Giuliani, N., Rizzoli, V. & Roodman, G. D. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 108, 3992\u20133996 (2006).","journal-title":"Blood"},{"key":"56506_CR5","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1200\/JCO.2001.19.15.3562","volume":"19","author":"GD Roodman","year":"2001","unstructured":"Roodman, G. D. Biology of osteoclast activation in cancer. J. Clin. Oncol. 19, 3562\u20133571 (2001).","journal-title":"J. Clin. Oncol."},{"key":"56506_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.692190","volume":"11","author":"H Liu","year":"2021","unstructured":"Liu, H. et al. Promotion of bone lesions through the myeloma integrin alpha6-mediated osteolytic signaling. Front. Oncol. 11, 692190 (2021).","journal-title":"Front. Oncol."},{"key":"56506_CR7","doi-asserted-by":"publisher","first-page":"eaay8203","DOI":"10.1126\/scisignal.aay8203","volume":"13","author":"Z Liu","year":"2020","unstructured":"Liu, Z. et al. Myeloma cells shift osteoblastogenesis to adipogenesis by inhibiting the ubiquitin ligase MURF1 in mesenchymal stem cells. Sci. Signal. 13, eaay8203 (2020).","journal-title":"Sci. Signal."},{"key":"56506_CR8","doi-asserted-by":"publisher","first-page":"6393","DOI":"10.1158\/0008-5472.CAN-12-2664","volume":"72","author":"J He","year":"2012","unstructured":"He, J. et al. p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction. Cancer Res. 72, 6393\u20136402 (2012).","journal-title":"Cancer Res."},{"key":"56506_CR9","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1056\/NEJMoa030847","volume":"349","author":"E Tian","year":"2003","unstructured":"Tian, E. et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med. 349, 2483\u20132494 (2003).","journal-title":"N. Engl. J. Med."},{"key":"56506_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31356-7","volume":"13","author":"H Liu","year":"2022","unstructured":"Liu, H. et al. Osteocyte CIITA aggravates osteolytic bone lesions in myeloma. Nat. Commun. 13, 3684 (2022).","journal-title":"Nat. Commun."},{"key":"56506_CR11","doi-asserted-by":"publisher","first-page":"eaau9087","DOI":"10.1126\/scitranslmed.aau9087","volume":"11","author":"H Liu","year":"2019","unstructured":"Liu, H. et al. Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease. Sci. Transl. Med. 11, eaau9087 (2019).","journal-title":"Sci. Transl. Med."},{"key":"56506_CR12","doi-asserted-by":"publisher","first-page":"eaan6282","DOI":"10.1126\/scisignal.aan6282","volume":"10","author":"J Yang","year":"2017","unstructured":"Yang, J. et al. C-reactive protein promotes bone destruction in human myeloma through the CD32-p38 MAPK-Twist axis. Sci. Signal 10, eaan6282 (2017).","journal-title":"Sci. Signal"},{"key":"56506_CR13","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm.4036","volume":"22","author":"KH Kim","year":"2016","unstructured":"Kim, K. H. & Roberts, C. W. Targeting EZH2 in cancer. Nat. Med. 22, 128\u2013134 (2016).","journal-title":"Nat. Med."},{"key":"56506_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109384","volume":"118","author":"X Yin","year":"2019","unstructured":"Yin, X., Yang, S., Zhang, M. & Yue, Y. The role and prospect of JMJD3 in stem cells and cancer. Biomed. Pharmacother. 118, 109384 (2019).","journal-title":"Biomed. Pharmacother."},{"key":"56506_CR15","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1515\/hsz-2019-0436","volume":"401","author":"SL Nutt","year":"2020","unstructured":"Nutt, S. L., Keenan, C., Chopin, M. & Allan, R. S. EZH2 function in immune cell development. Biol. Chem. 401, 933\u2013943 (2020).","journal-title":"Biol. Chem."},{"key":"56506_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3390\/genes7100083","volume":"7","author":"Y Yao","year":"2016","unstructured":"Yao, Y. et al. Downregulation of enhancer of zeste homolog 2 (EZH2) is essential for the induction of autophagy and apoptosis in colorectal cancer cells. Genes 7, 83 (2016).","journal-title":"Genes"},{"key":"56506_CR17","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.1016\/j.celrep.2018.03.002","volume":"22","author":"T Ito","year":"2018","unstructured":"Ito, T., Teo, Y. V., Evans, S. A., Neretti, N. & Sedivy, J. M. Regulation of cellular senescence by polycomb chromatin modifiers through distinct DNA damage- and histone methylation-dependent pathways. Cell Rep. 22, 3480\u20133492 (2018).","journal-title":"Cell Rep."},{"key":"56506_CR18","doi-asserted-by":"publisher","first-page":"947","DOI":"10.2741\/4760","volume":"24","author":"A Batool","year":"2019","unstructured":"Batool, A., Jin, C. & Liu, Y. X. Role of EZH2 in cell lineage determination and relative signaling pathways. Front. Biosci. 24, 947\u2013960 (2019).","journal-title":"Front. Biosci."},{"key":"56506_CR19","doi-asserted-by":"publisher","first-page":"11606","DOI":"10.1073\/pnas.1933744100","volume":"100","author":"CG Kleer","year":"2003","unstructured":"Kleer, C. G. et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl Acad. Sci. USA 100, 11606\u201311611 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"56506_CR20","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/cdd.2009.162","volume":"17","author":"ZL Wu","year":"2010","unstructured":"Wu, Z. L. et al. Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression. Cell Death Differ. 17, 801\u2013810 (2010).","journal-title":"Cell Death Differ."},{"key":"56506_CR21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.omtn.2019.02.010","volume":"16","author":"X Liu","year":"2019","unstructured":"Liu, X. et al. LINC00665 induces acquired resistance to gefitinib through recruiting EZH2 and activating PI3K\/AKT pathway in NSCLC. Mol. Ther. Nucleic Acids 16, 155\u2013161 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"56506_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7051","volume":"6","author":"D Zingg","year":"2015","unstructured":"Zingg, D. et al. The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. Nat. Commun. 6, 6051 (2015).","journal-title":"Nat. Commun."},{"key":"56506_CR23","first-page":"868","volume":"41","author":"J Ma","year":"2018","unstructured":"Ma, J., Zhang, J., Weng, Y. C. & Wang, J. C. EZH2-mediated microRNA-139-5p regulates epithelial-mesenchymal transition and lymph node metastasis of pancreatic cancer. Mol. Cells 41, 868\u2013880 (2018).","journal-title":"Mol. Cells"},{"key":"56506_CR24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ccr.2010.06.016","volume":"18","author":"C Lu","year":"2010","unstructured":"Lu, C. et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell 18, 185\u2013197 (2010).","journal-title":"Cancer Cell"},{"key":"56506_CR25","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature15520","volume":"527","author":"D Peng","year":"2015","unstructured":"Peng, D. et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527, 249\u2013253 (2015).","journal-title":"Nature"},{"key":"56506_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.27","volume":"7","author":"C Pawlyn","year":"2017","unstructured":"Pawlyn, C. et al. Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control. Blood Cancer J. 7, e549 (2017).","journal-title":"Blood Cancer J."},{"key":"56506_CR27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41420-020-00400-0","volume":"7","author":"K Ishiguro","year":"2021","unstructured":"Ishiguro, K. et al. Dual EZH2 and G9a inhibition suppresses multiple myeloma cell proliferation by regulating the interferon signal and IRF4-MYC axis. Cell Death Discov. 7, 7 (2021).","journal-title":"Cell Death Discov."},{"key":"56506_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0037-4","volume":"8","author":"E Terpos","year":"2018","unstructured":"Terpos, E., Ntanasis-Stathopoulos, I., Gavriatopoulou, M. & Dimopoulos, M. A. Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer J. 8, 7 (2018).","journal-title":"Blood Cancer J."},{"key":"56506_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02368-5","volume":"8","author":"JW Lee","year":"2017","unstructured":"Lee, J. W. et al. The HIV co-receptor CCR5 regulates osteoclast function. Nat. Commun. 8, 2226 (2017).","journal-title":"Nat. Commun."},{"key":"56506_CR30","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.3390\/ijms21082904","volume":"21","author":"Y Chang","year":"2020","unstructured":"Chang, Y. et al. Synovial fluid interleukin-16 contributes to osteoclast activation and bone loss through the JNK\/NFATc1 signaling cascade in patients with periprosthetic joint infection. Int J. Mol. Sci. 21, 2904 (2020).","journal-title":"Int J. Mol. Sci."},{"key":"56506_CR31","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1158\/1535-7163.MCT-15-0486","volume":"15","author":"H Hernando","year":"2016","unstructured":"Hernando, H. et al. EZH2 inhibition blocks multiple myeloma cell growth through upregulation of epithelial tumor suppressor genes. Mol. Cancer Ther. 15, 287\u2013298 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"56506_CR32","volume":"2022","author":"Y Wang","year":"2022","unstructured":"Wang, Y., Zhang, L., Yao, C., Ma, Y. & Liu, Y. Epithelial membrane protein 1 promotes sensitivity to RSL3-induced ferroptosis and intensifies gefitinib resistance in head and neck cancer. Oxid. Med Cell Longev. 2022, 4750671 (2022).","journal-title":"Oxid. Med Cell Longev."},{"key":"56506_CR33","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41388-023-02618-5","volume":"42","author":"X Yu","year":"2023","unstructured":"Yu, X. et al. Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader. Oncogene 42, 994\u20131009 (2023).","journal-title":"Oncogene"},{"key":"56506_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2005-6-13-246","volume":"6","author":"D Eckert","year":"2005","unstructured":"Eckert, D., Buhl, S., Weber, S., Jager, R. & Schorle, H. The AP-2 family of transcription factors. Genome Biol. 6, 246 (2005).","journal-title":"Genome Biol."},{"key":"56506_CR35","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","volume":"13","author":"R Duan","year":"2020","unstructured":"Duan, R., Du, W. & Guo, W. EZH2: a novel target for cancer treatment. J. Hematol. Oncol. 13, 104 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"56506_CR36","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1093\/nar\/27.20.4040","volume":"27","author":"LA McPherson","year":"1999","unstructured":"McPherson, L. A. & Weigel, R. J. AP2alpha and AP2gamma: a comparison of binding site specificity and trans-activation of the estrogen receptor promoter and single site promoter constructs. Nucleic Acids Res. 27, 4040\u20134049 (1999).","journal-title":"Nucleic Acids Res."},{"key":"56506_CR37","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/bonekey.2015.113","volume":"4","author":"E Terpos","year":"2015","unstructured":"Terpos, E., Confavreux, C. B. & Clezardin, P. Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma. Bonekey Rep. 4, 744 (2015).","journal-title":"Bonekey Rep."},{"key":"56506_CR38","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1182\/blood-2008-11-191577","volume":"114","author":"M Fulciniti","year":"2009","unstructured":"Fulciniti, M. et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114, 371\u2013379 (2009).","journal-title":"Blood"},{"key":"56506_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01890-w","volume":"8","author":"E Lazzari","year":"2017","unstructured":"Lazzari, E. et al. Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma. Nat. Commun. 8, 1922 (2017).","journal-title":"Nat. Commun."},{"key":"56506_CR40","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.cmet.2020.12.011","volume":"33","author":"Z Li","year":"2021","unstructured":"Li, Z. et al. Acetyl-CoA synthetase 2: a critical linkage in obesity-induced tumorigenesis in myeloma. Cell Metab. 33, 78\u201393e77 (2021).","journal-title":"Cell Metab."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56506-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56506-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56506-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T02:44:14Z","timestamp":1738291454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56506-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["56506"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-56506-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]},"assertion":[{"value":"11 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1206"}}